Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating whether adding revumenib to standard intensive chemotherapy improves outcomes for participants newly diagnosed with acute myeloid leukemia AML who have a specific NPM1 genetic mutation. This Phase 3 study also assesses the safety of combining revumenib with chemotherapy compared to chemotherapy alone. Participants must be eligible for intensive chemotherapy and meet specific health and mutation criteria. Participants will be randomly assigned to one of two groups one group receives revumenib orally combined with an intensive chemotherapy regimen of cytarabine and daunorubicin given by intravenous infusion, while the other group receives a placebo orally with the same chemotherapy regimen. The study is double-blind, so neither participants nor researchers know who receives revumenib or placebo during the trial. Treatment and assessments will continue with regular monitoring. During the study, participants undergo multiple assessments including evaluation of event-free survival and measurable residual disease complete remission rates over up to 2 years. Additional outcomes like overall survival and response rates are tracked up to 5 years. Safety is monitored by recording treatment-emergent adverse events and changes in patient-reported fatigue. Participants will have various clinical visits and laboratory tests throughout the treatment and follow-up periods to evaluate effectiveness and safety.